Top Medical Searches

France’s Cellectis wins U.S patents for gene editing technology

PARIS (Reuters) – The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

 Read more…

Be Sociable, Share!
February 13th, 2018 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us